
Novel developments in lower-risk MDS & important practical considerations when treating patients
VJHemOnc Podcast
Innovative Treatments for Anemic Lower-Risk MDS
This chapter explores the current strategies for treating anemic lower-risk myelodysplastic syndromes (MDS) patients, particularly focusing on erythropoiesis-stimulating agents (ESAs) and the emerging use of Luspatercept. The discussion highlights the nuances of treatment decisions based on individual patient characteristics, EPO levels, and transfusion dependence, while comparing practices in Europe and the U.S. Additionally, the chapter examines ongoing trials and the potential implications of adjusting current treatment protocols.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.